Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation for COVID-19 Patients
Evidence Based Medicine presented by InpharmD™ · InpharmD™
April 16, 20218m 15s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A randomized, open-label, trial conducted to evaluate the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU).